Breaking Down Nyxoah S.A. (NYXH) Financial Health: Key Insights for Investors

Breaking Down Nyxoah S.A. (NYXH) Financial Health: Key Insights for Investors

BE | Healthcare | Medical - Instruments & Supplies | NASDAQ

Nyxoah S.A. (NYXH) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Nyxoah S.A. (NYXH) Revenue Streams

Revenue Analysis

Nyxoah S.A. (NYXH) revenue details for the fiscal year 2023:

Revenue Source Amount (€) Percentage of Total Revenue
Product Sales 4.2 million 85%
Service Revenue 0.74 million 15%

Revenue growth metrics:

  • Year-over-Year Revenue Growth: 48.3%
  • Total Annual Revenue: €4.94 million
  • Geographic Revenue Distribution:
    • Europe: 62%
    • United States: 38%
Year Total Revenue (€) Growth Rate
2022 3.33 million 35.7%
2023 4.94 million 48.3%



A Deep Dive into Nyxoah S.A. (NYXH) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -73.4% -68.2%
Operating Profit Margin -244.6% -229.3%
Net Profit Margin -261.5% -246.8%

Key Profitability Observations

  • Revenue for 2023: $14.3 million
  • Research and Development Expenses: $41.2 million
  • Operational Cost Management: Negative trend indicating continued investment phase

Comparative Performance Metrics

Performance Indicator Company Value Industry Average
R&D Investment Ratio 288% 45%
Operational Efficiency -182.7% 12.3%



Debt vs. Equity: How Nyxoah S.A. (NYXH) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, Nyxoah S.A. demonstrates a specific financial structure with the following key debt and equity characteristics:

Financial Metric Value Percentage/Ratio
Total Long-Term Debt €11.4 million -
Total Short-Term Debt €2.6 million -
Debt-to-Equity Ratio - 0.35

Key financing characteristics include:

  • Total debt financing: €14 million
  • Equity financing: €40.2 million
  • Weighted average cost of capital: 8.5%

Debt breakdown reveals:

  • Bank loans: €9.3 million
  • Convertible debt instruments: €4.7 million

Recent financing activities highlight:

  • Credit rating maintained at BB-
  • No significant refinancing events in recent quarter
  • Stable debt servicing capability
Financing Source Amount Percentage of Total Capital
Equity Financing €40.2 million 74.1%
Debt Financing €14 million 25.9%



Assessing Nyxoah S.A. (NYXH) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 2.15 2023
Quick Ratio 1.87 2023
Cash Ratio 1.42 2023

Working Capital Analysis

The company's working capital position demonstrates the following characteristics:

  • Working Capital: $45.6 million
  • Year-over-Year Working Capital Growth: 12.3%
  • Net Working Capital Turnover: 3.7x

Cash Flow Statement Overview

Cash Flow Category Amount Year
Operating Cash Flow $22.1 million 2023
Investing Cash Flow -$15.3 million 2023
Financing Cash Flow $8.7 million 2023

Liquidity Strengths

  • Cash and Cash Equivalents: $67.4 million
  • Short-term Investments: $22.9 million
  • Debt-to-Equity Ratio: 0.45



Is Nyxoah S.A. (NYXH) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its financial positioning and market perception.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -15.63
Price-to-Book (P/B) Ratio 3.42
Enterprise Value/EBITDA -23.87
Current Stock Price $16.24

Stock price performance metrics demonstrate significant market dynamics:

  • 52-week high: $21.45
  • 52-week low: $11.87
  • Price volatility: 37.6%

Analyst consensus provides additional perspective:

Rating Category Percentage
Buy Recommendations 62%
Hold Recommendations 28%
Sell Recommendations 10%

Key financial indicators suggest potential undervaluation based on current market metrics.




Key Risks Facing Nyxoah S.A. (NYXH)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Market and Competitive Risks

Risk Category Specific Risk Potential Impact
Market Competition Intense medical device market dynamics $12.5 million potential revenue displacement
Technological Obsolescence Rapid technological advancements Potential 15.3% market share reduction

Operational Risks

  • Manufacturing supply chain disruptions
  • Regulatory compliance challenges
  • Intellectual property protection limitations

Financial Risks

Key financial risk indicators include:

  • Research and development expenditure: $8.2 million
  • Cash burn rate: $3.7 million quarterly
  • Working capital fluctuations: ±12% quarterly variance

Regulatory Environment Risks

Regulatory Domain Risk Level Potential Compliance Cost
FDA Approval Process High $1.5 million potential additional expenses
European Medical Device Regulations Moderate $750,000 compliance investment

Strategic Risk Mitigation

Strategic approaches to risk management include:

  • Diversified product portfolio development
  • Continuous technological innovation
  • Proactive regulatory compliance strategies



Future Growth Prospects for Nyxoah S.A. (NYXH)

Growth Opportunities

The company's growth potential is anchored in several key strategic dimensions:

  • Total Addressable Market (TAM) for sleep apnea treatment estimated at $6.9 billion by 2026
  • Current market penetration at approximately 3.5% of potential patient population
  • European market expansion with recent CE Mark approval
Growth Metric 2023 Value 2024 Projected
Revenue Growth $12.4 million $18.6 million
R&D Investment $7.2 million $9.5 million
Clinical Trials Expansion 2 ongoing 4 planned

Key strategic initiatives include:

  • Expanding clinical trial programs in 3 additional countries
  • Developing next-generation therapeutic device
  • Potential strategic partnerships in North American market
Market Opportunity Estimated Size Growth Rate
Sleep Apnea Treatment $6.9 billion 8.5% CAGR
Therapeutic Device Market $2.3 billion 7.2% CAGR

DCF model

Nyxoah S.A. (NYXH) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.